The European Medicines Agency has provided Johnson & Johnson (NYSE: JNJ) with its first regulatory approval for Akeega (niraparib/abiraterone acetate).
The dual action tablet, which is given with prednisone or prednisolone, is approved for certain adults with metastatic castration-resistant prostate cancer (mCRPC) and BRCA mutations.
Akeega will be made available to treat people for whom chemotherapy is not appropriate.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze